Niagen Bioscience, Inc. financial data

Symbol
NAGE on Nasdaq
Industry
Medicinal Chemicals & Botanical Products
Location
10900 Wilshire Blvd, Suite 600, Los Angeles, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
ChromaDex Corp. (to 3/10/2025), CODY RESOURCES, INC. (to 6/24/2008)
Latest financial report
10-K - Q4 2024 - Mar 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 294 % +20.2%
Quick Ratio 60 % -8.89%
Debt-to-equity 66.2 % -29.7%
Return On Equity 24.4 %
Return On Assets 14.7 %
Operating Margin 7.76 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77.8M shares +3.24%
Common Stock, Shares, Outstanding 77.3M shares +3.13%
Entity Public Float 143M USD +76%
Common Stock, Value, Issued 77K USD +2.67%
Weighted Average Number of Shares Outstanding, Basic 75.9M shares +1.26%
Weighted Average Number of Shares Outstanding, Diluted 78.1M shares +4.19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 99.6M USD +19.2%
Cost of Revenue 38M USD +15.9%
Research and Development Expense 6.02M USD +21.3%
Selling and Marketing Expense 29.5M USD +11.5%
General and Administrative Expense 18.4M USD -26.5%
Operating Income (Loss) 7.73M USD
Net Income (Loss) Attributable to Parent 8.55M USD +6197%
Earnings Per Share, Basic 0.11 USD/shares
Earnings Per Share, Diluted 0.11 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44.5M USD +63.6%
Accounts Receivable, after Allowance for Credit Loss, Current 7.1M USD
Inventory, Net 9.19M USD -36.7%
Assets, Current 64.1M USD +29.4%
Operating Lease, Right-of-Use Asset 1.73M USD -27.9%
Intangible Assets, Net (Excluding Goodwill) 359K USD -29.6%
Other Assets, Noncurrent 368K USD -3.92%
Assets 68.3M USD +24.2%
Accounts Payable, Current 8.53M USD -16.7%
Accrued Liabilities, Current 7.82M USD -17.7%
Liabilities, Current 17.9M USD -13%
Contract with Customer, Liability, Noncurrent 2.58M USD -22.1%
Operating Lease, Liability, Noncurrent 1.66M USD -35.3%
Liabilities 22.2M USD -16.3%
Retained Earnings (Accumulated Deficit) -182M USD +4.49%
Stockholders' Equity Attributable to Parent 46.1M USD +62%
Liabilities and Equity 68.3M USD +24.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 295K USD -89.4%
Net Cash Provided by (Used in) Financing Activities -14K USD
Net Cash Provided by (Used in) Investing Activities -41K USD +54.9%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 77.3M shares +3.13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 240K USD -91.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 44.7M USD +63.4%
Deferred Tax Assets, Valuation Allowance 44.3M USD -4.53%
Deferred Tax Assets, Gross 44.7M USD -4.43%
Operating Lease, Liability 2.64M USD -20%
Depreciation 178K USD -21.9%
Lessee, Operating Lease, Liability, to be Paid 2.91M USD -22.2%
Operating Lease, Liability, Current 982K USD +42.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 901K USD -20.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.14M USD +36.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 275K USD -44.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 491K USD -45.5%
Deferred Tax Assets, Operating Loss Carryforwards 35.2M USD -4.11%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 357K USD -27.3%
Operating Lease, Payments 91K USD -49.4%
Additional Paid in Capital 228M USD +4.15%
Amortization of Intangible Assets 38K USD -7.32%
Deferred Tax Assets, Net of Valuation Allowance 386K USD +7.82%